对B-NHL淋巴瘤相关基因突变联合检测的研究

Study of combined 2 types of PCR gene diagnosis to B-NHL

目的探讨联合检测IgH基因单克隆性重排带及BCL-2IgH(MBR)融合基因,对B-NHL淋巴瘤诊断及化疗前、后微小残留灶克隆性变化监测的意义。方法采用上述两种靶基因突变检测的PCR方法各两种,检测B-NHL组患者及非淋巴瘤肿瘤组患者各30例,观察化疗前、后的检出阳性率及变化,同时设健康对照30例。结果联合两种方法对B-NHL淋巴瘤治疗前患者WBC基因组DNA中的IgH基因96·6%呈单克隆重排带,化疗后原来单克隆重排带者有1例转阴,2例转为2克隆性,2例转为3克隆性;两组对照阴性。B-NHL淋巴瘤患者中38·3%BCL-2/IgH(MBR)融合基因阳性,非淋巴瘤肿瘤组患者为10·0%,健康人为6·6%;联合两种方法对B-NHLBCL-2IgH(MBR)的总检出阳性率为38·3%。结论联合检测IgH基因重排及BCL-2/IgH(MBR)融合基因可提高B-NHL的诊断率,IgH基因单克隆重排带在B-NHL,化疗前后检测对监测B-NHL微小残留灶克隆性变化有一定意义。

Objective： Use 2 types of PCR methods to check the IgH gene rearangement and BCL -2IgH fused gene in B - NHL, and monitoring the chages of B - NHL MBD. Methods： Use the methods above to check the genome of B - NHL, Non - NHL tumor and normal people 30 cases for each. Results ： B - NHL group had 96. 6% monoceonal IgH rearangement, after chemical therapy 2 cases had 2 clonal IgH rearangements, another 2 cases had 3 clonal IgH rearangements. B - NHL group had 38.3% BCL - 2 IgH （MBR） fused gene, Non -NHL tumor group had 10. 0% fused gene, and normal people had 6. 6% fused gene. Conclution： The combination of 2 type of PCR methods to check the IgH gene rearangement and BCL - 2/IgH fused gene can rise the positive rate of B - NHL diagnosis.